

April 12, 2026

To  
The Listing Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Clarification on Increase in volume.**

This is in reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and with respect to NSE letter No. NSE/CM/Surveillance/16803 dated April 10, 2026 seeking clarification on the increase of in volume of the shares of the Company traded on the Exchanges

The Company confirms that there is no pending information and/or announcement which, in terms of Regulation 30 of the SEBI Listing Regulations is required to be disclosed to the Stock Exchanges and which, in our opinion, may have a bearing on the price/volume behaviour of the Company's scrip.

Further, we would like to state that the movement in the volume of equity shares of the Company is purely market-driven and attributable to prevailing market conditions.

The Company has been regularly notifying all Unpublished Price Sensitive Information ("UPSI"), as and when required, in compliance with Regulation 30 and other applicable provisions of the SEBI Listing Regulations.

This above clarification may please be taken on record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Sisir K. Mishra**  
*Company Secretary & Compliance Officer*

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)

